Polymorphic forms of 3-(4-amino-1-oxo-1,3...

Details Polymorphic forms of 3-(4-amino-1-oxo-1,3... Polymorphic forms of 3-(4-amino-1-oxo-1,3...

2008-12-15

2010-12-21

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S200000

Reexamination Certificate

active

07855217

ABSTRACT:
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.

REFERENCES:
patent: 3536809 (1970-10-01), Applezwcig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4810643 (1989-03-01), Souza
patent: 4999291 (1991-03-01), Souza
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5229496 (1993-07-01), Deeley et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5391485 (1995-02-01), Deeley et al.
patent: 5393870 (1995-02-01), Deeley et al.
patent: 5528823 (1996-06-01), Rudy, Jr. et al.
patent: 5580755 (1996-12-01), Souza
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698579 (1997-12-01), Muller
patent: 5712291 (1998-01-01), D'Amato
patent: 5731325 (1998-03-01), Andrulis, Jr. et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5798368 (1998-08-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6114335 (2000-09-01), D'Amato
patent: 6114355 (2000-09-01), D'Amato
patent: 6140346 (2000-10-01), Andrulis, Jr. et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6326388 (2001-12-01), Man et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 7112602 (2006-09-01), D'Amato et al.
patent: 7465800 (2008-12-01), Jaworsky et al.
patent: 2001/0018445 (2001-08-01), Huang et al.
patent: 2001/0056114 (2001-12-01), D'Amato
patent: 2002/0035090 (2002-03-01), Zeldis et al.
patent: 2002/0045643 (2002-04-01), Muller et al.
patent: 2002/0052398 (2002-05-01), D'Amato
patent: 2002/0054899 (2002-05-01), Zeldis
patent: 2002/0061923 (2002-05-01), D'Amato
patent: 2002/0128228 (2002-09-01), Hwu
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2002/0183360 (2002-12-01), Muller et al.
patent: 2003/0013739 (2003-01-01), Masferrer et al.
patent: 2003/0028028 (2003-02-01), Man et al.
patent: 2003/0045552 (2003-03-01), Robarge et al.
patent: 2003/0069428 (2003-04-01), Muller et al.
patent: 2003/0096841 (2003-05-01), Robarge et al.
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2003/0144325 (2003-07-01), Muller et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2003/0187024 (2003-10-01), D'Amato
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2003/0235909 (2003-12-01), Hariri et al.
patent: 2004/0029832 (2004-02-01), Zeldis
patent: 2004/0077685 (2004-04-01), Figg et al.
patent: 2004/0077686 (2004-04-01), Dannenberg et al.
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0122052 (2004-06-01), Muller et al.
patent: 2004/0220144 (2004-11-01), Zeldis
patent: 2004/0266809 (2004-12-01), Emanuel et al.
patent: 2005/0203142 (2005-09-01), Zeldis
patent: 2006/0052609 (2006-03-01), Muller et al.
patent: 2008/0064876 (2008-03-01), Muller et al.
patent: 2008/0132541 (2008-06-01), Zeldis et al.
patent: 2009/0062343 (2009-03-01), Jaworsky et al.
patent: 2009/0149449 (2009-06-01), Liu et al.
patent: 2009/0149499 (2009-06-01), Jaworsky et al.
patent: 2009/0176832 (2009-07-01), Jaworsky et al.
patent: 2009/0187023 (2009-07-01), Jaworsky et al.
patent: A H10-53576 (1998-02-01), None
patent: A 2001-503384 (2001-03-01), None
patent: WO97/46526 (1997-12-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO98/03502 (1998-01-01), None
patent: WO 98/54170 (1998-12-01), None
patent: WO 01/70275 (2001-09-01), None
patent: WO 01/87307 (2001-11-01), None
patent: WO 02/059106 (2002-08-01), None
patent: WO 02/064083 (2002-08-01), None
patent: PCT/US03/11578 (2003-01-01), None
patent: WO 03097052 (2003-11-01), None
patent: WO02/26737 (2004-04-01), None
patent: WO 2004103274 (2004-12-01), None
patent: WO 2005023192 (2005-03-01), None
patent: WO 2006/028964 (2006-03-01), None
patent: WO 2007/136640 (2007-11-01), None
patent: WO 2009/111948 (2009-09-01), None
patent: WO 2009/114601 (2009-09-01), None
patent: WO 2010/054833 (2010-05-01), None
patent: WO 2010/056384 (2010-05-01), None
patent: WO 2010/061209 (2010-06-01), None
patent: WO 2010/100476 (2010-09-01), None
Dimartino et al., 1997, “Preparation and physical characterization of forms II and III of paracetamol,” J. Thermal Analysis 48:447-458.
Jonsson, 1972, “Chemical structure and teratogenic properties. 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues,” Acta. Pharm. Suec. 9(6):521-542.
Wilen et al., 1977, “Strategies in optical resolutions,” Tetrahedron 33:2725-2736.
Wilen, 1972, Tables of Resolving Agents and Optical Resolutions, Eliel, ed., U. Notre Dame Press, Notre Dame, IN pp. 268.
Wolff, ed., 1995, 1 Burger's Medicinal Chemistry and Drug Discovery, 5th ed., pp. 172-178 and 949-982.
Corral et al., 1999, “Immunomodulation by thalidomide and thalidomide analogs,” Ann. Rheum. Dis. 58(Supp. 1):1107-1113.
Grant, 1999, “Theory and Origin of Polymorphism,” in Polymorphism in Pharmaceutical Solids, Minneapolis, MN, Ch. 1, pp. 1-10.
He, W., et al., 1993, 206th American Chemical Society, Chicago, IL; Med. Chem., paper 216.
Lentzsch et al., 2002, “S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice,” Cancer Research 62:2300-2305.
Muller et al., 1999, “Amino-substituted thalidomide analogs: Potent inhibitors of TNF-{umlaut over (γ)} production,” Bioorg. Med. Chem. Lett. 9:1625-1630.
Muller et al., 1998, “Thalidomide analogs and PDE4 inhibition,” Bioorg. Med. Chem. Lett. 8:2669-2674.
Muller et al., 1996, “Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity,” J. Med. Chem. 39:3238-3240.
Anderson, “Moving disease biology from the laboratory to the clinic,”Seminars in Oncology, 2002 29:17-20.
Barlogie et al., “High-dose therapy immunomodulatory drugs in multiple myeloma,”Seminars in Oncology, 2002, 29 (6):26-33.
Barlogie et al., “Introduction: Thalidomide and the IMiDs in multiple myeloma,”Seminars in Hematology, 2003, 40 (4):1-2.
Barlogie et al., “Total Therapy II (TTII) for newly diagnosed multiple myeloma (MM): preliminary data on feasibility and efficacy in the first 231 enrolled patients; comparison with predecessor trial total therapy I ((TTI) (N=231),”Blood, Abstract# 2857, Dec. 7-11, 2001,American Society of Hematology.
Barlogie, “Thalidomide and CC-5013 in Multiple Myeloma: The University of Arkansas experience.”Seminars in Hematology, 2003, 40 (4):33-38.
Bartlett et al., “Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers,”British Journal of Cancer, 2004, 90:955-961.
Bartlett et al., “The evolution of thalidomide a

Affiliated with

Also associated with

Rating

Polymorphic forms of 3-(4-amino-1-oxo-1,3... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymorphic forms of 3-(4-amino-1-oxo-1,3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic forms of 3-(4-amino-1-oxo-1,3... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4199411